What is Wedbush's Estimate for WVE Q1 Earnings?

Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Wedbush issued their Q1 2025 earnings per share (EPS) estimates for shares of Wave Life Sciences in a research note issued on Tuesday, April 8th. Wedbush analyst Y. Zhong anticipates that the company will post earnings of ($0.27) per share for the quarter. Wedbush has a "Outperform" rating and a $18.00 price objective on the stock. The consensus estimate for Wave Life Sciences' current full-year earnings is ($1.14) per share. Wedbush also issued estimates for Wave Life Sciences' Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.04) EPS and FY2026 earnings at ($1.14) EPS.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.34. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The firm had revenue of $83.75 million during the quarter, compared to analysts' expectations of $25.60 million.

Several other research analysts have also recently weighed in on the stock. StockNews.com upgraded shares of Wave Life Sciences from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. HC Wainwright reiterated a "buy" rating and issued a $22.00 price target on shares of Wave Life Sciences in a research note on Wednesday, March 26th. Finally, Jefferies Financial Group began coverage on Wave Life Sciences in a report on Tuesday, February 25th. They issued a "buy" rating and a $26.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Wave Life Sciences presently has an average rating of "Moderate Buy" and an average target price of $22.18.

Wave Life Sciences Price Performance

Shares of Wave Life Sciences stock traded down $0.30 during trading hours on Friday, hitting $5.98. The company's stock had a trading volume of 297,509 shares, compared to its average volume of 1,181,910. Wave Life Sciences has a 12 month low of $4.25 and a 12 month high of $16.74. The company has a market capitalization of $917.85 million, a PE ratio of -5.39 and a beta of -0.93. The stock has a 50 day moving average of $9.21 and a 200 day moving average of $11.63.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. boosted its position in shares of Wave Life Sciences by 209.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 844,617 shares of the company's stock worth $6,926,000 after purchasing an additional 571,345 shares in the last quarter. FMR LLC grew its stake in Wave Life Sciences by 174.5% in the third quarter. FMR LLC now owns 1,540,190 shares of the company's stock valued at $12,630,000 after acquiring an additional 979,110 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Wave Life Sciences by 477.7% during the third quarter. BNP Paribas Financial Markets now owns 41,828 shares of the company's stock valued at $343,000 after acquiring an additional 34,588 shares in the last quarter. State Street Corp raised its position in shares of Wave Life Sciences by 2.6% during the third quarter. State Street Corp now owns 2,321,248 shares of the company's stock worth $19,034,000 after purchasing an additional 57,822 shares during the period. Finally, Jane Street Group LLC lifted its holdings in shares of Wave Life Sciences by 33.3% in the 3rd quarter. Jane Street Group LLC now owns 142,014 shares of the company's stock worth $1,165,000 after purchasing an additional 35,472 shares in the last quarter. 89.73% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Paul Bolno sold 169,025 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $9.57, for a total value of $1,617,569.25. Following the transaction, the chief executive officer now owns 338,351 shares in the company, valued at approximately $3,238,019.07. The trade was a 33.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christian O. Henry sold 10,500 shares of Wave Life Sciences stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total transaction of $102,585.00. Following the transaction, the director now directly owns 16,115 shares of the company's stock, valued at $157,443.55. This represents a 39.45 % decrease in their position. The disclosure for this sale can be found here. Insiders own 29.10% of the company's stock.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.